ErbB2 (Her-2) and p53 Antibodies

ErbB2 (Her-2) and p53 Antibodies

With a focus on providing targeted solutions for cancer research, AnaSpec is pleased to introduce two brand-new additions to our growing array of highly specific antibody products: c-erbB-2 (HER-2/ neu) and p53 polyclonal antibodies.

c-erbB-2 (HER-2/ neu) Antibodies

The overexpression of the c-erbB-2 (HER-2/neu) gene product, a 185 kDa transmembrane receptor protein, is associated with cell transformation and tumorigenesis. It shares homology with the epidermal growth factor receptor and has intrinsic tyrosine kinase activity, HER-2/neu gene is amplified and overexpressed in 25-30% of human breast and ovarian cancers. Overexpression of the protein, as determined by immunohistochemistry, is associated with poor prognosis1,2. AnaSpec’s polyclonal anti-ErbB2 (Her-2) has been proven to work in such applications as: (A) Western blot, 25 μg of MCF-7 cell lysate was loaded in each lane and the immunoblot incubated with anti-Her-2 antibody at 1:500 dilution and (B) IHC, human breast cancer cells incubated with anti-Her-2 antibody at 2 μg/ml.

Anti-C-erbB-2100 µg29559

p53 Antibodies

One of the most important mammalian cell cycle checkpoint proteins is the tumor suppressor protein, p53. In normal, undamaged cells, p53 is rapidly degraded. However, when cells are treated with DNA damage-inducing agents, there is a transient accumulation of p53 protein and it is activated as a transcription factor. In several types of human cancers, p53 is mutated3,4. Human p53 protein has been shown to be phosphorylated at several N-terminal and C-terminal sites that affect site-specific DNA binding and interaction with other cellular and viral proteins in vitro5-10. Phosphorylation at serines 6, 9, 15, 20, 33, 37 occurs after cells are exposed either to ionizing radiation or to UV light11,12. Serines 6 and 15 were demonstrated to be among the strongest and earliest phosphorylated sites in response to DNA damage-induced posttranslational modifications13,14. AnaSpec’s collection of p53 antibody products includes both phosphospecific and non-phosphospecific solutions. Shown below are western blots of hydroxyurea-treated Cos-7 cells expressing an increasing amount of phosphorylated serine p53’s.

Anti-P53 (pSer6), phospho-specific50 µg28006-50
Anti-P53 (Paired6), non-phospho-specific0.1 mg28007
Anti-P53 (pSer9), phospho-specific50 µg28008-50
Anti-P53 (Paired9), non-phospho-specific0.1 mg28009
Anti-P53 (pSer15), phospho-specific50 µg28010-50
Anti-P53 (Paired15), non-phospho-specific0.1 mg28011

To view a full list of primary and secondary (fluorescent and non-fluorescent) antibodies, click here

To request AnaSpec’s 2006-2007 Detection Reagents & Kits catalog, click here

1. Hudson, LG. et al. J. Biol. Chem. 265, 2389 (1990).
2. Reese, DM and DJ. Slamon. Stem Cells 15, 1 (1997).
3. Brown, JM. et al. Cancer Res. 59, 1391(1999).
4. Albrechtsen, N. et al. Oncogene 18, 7706 (1999).
5. Wang, L. et al. J. Biol Chem. 276, 43604 (2001).
6. Xirodimas, D. et al. Oncogene 20, 4972 (2001).
7. Backlund, MG. et al. Cancer Res. 61, 6577 (2001).
8. Sakaguchi, K. et al. J. Biol. Chem. 275, 9278 (2000).
9. Banin, S. et al. Science 281, 1674 (1998).
10. Canman, CE. et al. Science 281, 1677 (1998).
11. Burns, TF. and El-Deiry, WS. J. cell Physiol. 181, 231 (1999).
12. Oren, M. et al. J. Biol. Chem 274, 36031 (1999).
13. Lakin, ND. et al Oncogene 18, 7644 (1999).
14. Higashimoto, Y. et al. J. Biol. Chem. 275, 23199 (2000).